Effects of aripiprazole combined with risperidone on cognitive function and serological indices in patients with schizophrenia
Objective:To investigate the efficacy of aripiprazole combined with risperidone in schizophrenia and its effects on cognitive function and serological indicators.Methods:Sixty patients with schizophrenia who were admitted to our hospital between January 2021 and January 2023 were divided into a control group(30 patients)and an observation group(30 cases)using a random number table method.The control group was treated with risperidone,starting at 1 mg/day and gradually increasing the dose according to the progression of the disease,up to 4～6 mg/dayonce/day.The observation group was treated with aripiprazole combined with risperidone,starting with 1 mg/d risperidone,increasing to 2 mg/d once/d on the 3rd day;at the same time,aripiprazole tablets were added,the initial dose was 5 mg/d,and the dose was increased to 10 mg/d once/d after 2 days,and then gradually increased from 5 mg and adjusted to 20～25 mg/d according to the patient's condition.Both groups were treated for eight weeks.Clinical efficacy,positive and negative symptom scale(PANSS)scores,easy mental status examination(MMSE),serological parameters[phosphorylated rapamycin target protein(P-mTOR),core proteoglycans],inflammatory factor levels[interleukin-1 β,tumor necrosis factor alpha(TNF-α),interleukin-6(IL-6)],and adverse reactions were compared between the two groups.Results:Compared to the control group,the total effective rate of the observation group was higher after treatment(P＜0.05),and there was no significant difference in PANSS scores between the two groups before treatment(P＞0.05).After treatment,the PANSS scores of both groups were lower than those before treatment,and the observation group had lower PANSS scores than the control group(P＜0.05).There was no significant difference in the cognitive function scores between the two groups before treatment(P＞0.05).The cognitive function scores of the two groups after treatment were higher than those before treatment,and the observation group had higher scores than the control group(P＜0.05).Before treatment,there was no significant difference in the serological indices between the two groups(P＞0.05).After treatment,the P-mTOR level was lower than before treatment,and the core proteoglycan level was higher than before treatment.The serum P-mTOR level in the observation group was lower than that in the control group and the core proteoglycan level was higher than that in the control group(P＜0.05).There was no significant difference in the levels of inflammatory factors between the two groups before treatment(P＞0.05).The levels of inflammatory factors in the two groups after treatment were lower than those before treatment,and those in the observation group were lower than those in the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusions:Combination therapy with aripiprazole and risperidone in patients with schizophrenia can improve treatment efficacy,enhance cognitive ability,regulate serum indicators,effectively inhibit inflammatory reactions in the body,and reduce the incidence of adverse reactions.Therefore,it is worth promoting its clinical use.
万方数据
维普
